<DOC>
	<DOCNO>NCT00003720</DOCNO>
	<brief_summary>RATIONALE : SU5416 may stop growth Kaposi 's sarcoma stopping blood flow tumor . PURPOSE : Phase I trial study effectiveness SU5416 treat patient AIDS-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>SU5416 Treating Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety tolerability SU5416 patient AIDS-related Kaposi 's sarcoma . II . Determine pharmacokinetics regimen patient . III . Evaluate antitumor effect biological activity regimen patient . IV . Determine safety regimen HIV replication immune parameter patient . OUTLINE : This dose escalation , multicenter study . Patients receive SU5416 intravenous injection twice weekly 4 week . Patients may continue treatment maximum 1 year absence disease progression unacceptable toxicity . In absence dose limit toxicity ( DLT ) first 6 patient treat , subsequent cohort 6 patient receive escalate dos SU5416 schedule . If DLT occur 2 6 patient give dose level , dose escalation cease next low dose declare maximum tolerate dose ( MTD ) . Six additional patient treat MTD . Patients follow 30 day last treatment , every 3 month thereafter . PROJECTED ACCRUAL : This study accrue maximum 30 patient .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy prove Kaposi 's sarcoma stable progress receive standard therapy HIV positive No severe pulmonary Kaposi 's sarcoma Five measurable lesion least 10 mm lesion present least 30 day OR KSrelated generalize edema edema extremity without evidence active mucocutaneous lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 750/mm3 without transfusion Hemoglobin least 8.0 g/dL without transfusion Platelet count least 50,000/mm3 without transfusion Hepatic : AST/ALT great 2.5 time upper limit normal ( ULN ) Bilirubin great 2.0 mg/dL ( 3.0 mg/dL concurrent indinavir therapy ) Renal : Creatinine great 1.8 mg/dL OR Creatinine clearance least 50 mL/min Other : Not pregnant Fertile patient must use effective contraception No known allergy Cremophor Cremophor base drug product No concurrent uncontrolled serious infection : Pneumocystis carinii pneumonia Toxoplasma brain abscess CMV retinitis colitis Cryptococcal meningitis Symptomatic Mycobacterium aviumintracellulare No active malignancy except : Basal cell carcinoma skin Carcinoma situ cervix No acute chronic medical psychiatric condition PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior biologic therapy AIDSrelated Kaposi 's sarcoma At least 2 week since prior immunotherapy AIDSrelated Kaposi 's sarcoma recover At least 2 week since prior epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) No concurrent immunotherapy Chemotherapy : At least 2 week since prior chemotherapy AIDSrelated Kaposi 's sarcoma recover No concurrent chemotherapy Endocrine therapy : At least 2 week since prior hormonal therapy AIDSrelated Kaposi 's sarcoma No concurrent hormonal therapy ( include betaHCG ) Radiotherapy : Recovered prior radiotherapy No concurrent radiotherapy Surgery : At least 4 week since prior surgery recover No prior biopsy measurable lesion Other : No prior laser therapy measurable lesion Stable antiretroviral therapy least 2 week At least 3 week since investigational drug No concurrent local topical therapy disease No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
</DOC>